Evidence map›Paper›PMID 39064398›Full record

ArticleMicromachines2024

DEMIGOD: A Low-Cost Microcontroller-Based Closed-Loop System Integrating Nanoengineered Sweat-Based Glucose Monitoring and Controlled Transdermal Nanoemulsion Release of Hypoglycemic Treatment with a Software Application for Noninvasive Personalized Diabetes Care.

Vasiliki Fiska, Eirini Papanikolaou, Michaela Patila, Mamas I Prodromidis, Maria G Trachioti, Eleni I Tzianni, Konstantinos Spyrou, Pantelis Angelidis, Markos G Tsipouras

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Micromachines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vasiliki FiskaDepartment of Electrical and Computer Engineering, University of Western Macedonia, 50100 Kozani, Greece.ORCID 0000-0002-9801-6507
Eirini PapanikolaouLaboratory of Physiology, Faculty of Medicine, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0002-1554-2430
Michaela PatilaBiotechnology Laboratory, Department of Biological Applications and Technologies, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0003-1051-9001
Mamas I ProdromidisLaboratory of Analytical Chemistry, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0002-1309-403X
Maria G TrachiotiLaboratory of Analytical Chemistry, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0001-8271-0134
Eleni I TzianniLaboratory of Analytical Chemistry, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0001-5734-0215
Konstantinos SpyrouDepartment of Materials Science and Engineering, University of Ioannina, 45110 Ioannina, Greece.ORCID 0000-0002-2032-8439
Pantelis AngelidisDepartment of Electrical and Computer Engineering, University of Western Macedonia, 50100 Kozani, Greece.ORCID 0000-0003-1503-8952
Markos G TsipourasDepartment of Electrical and Computer Engineering, University of Western Macedonia, 50100 Kozani, Greece.ORCID 0000-0002-6757-1698

Funding

European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH - CREATE - INNOVATE T2EDK-02171
6 · The paper itself

Abstract

This study endeavored to design and develop an innovative closed-loop diagnostic and therapeutic system with the following objectives: (a) the noninvasive detection of glucose concentration in sweat utilizing nanonengineered screen-printed biosensors; (b) the management of measured data through a specialized computer system comprising both hardware and software components, thereby enabling the precise control of therapeutic responses via a patch-based nanomedicine delivery system. This initiative addresses the significant challenges inherent in the management of diabetes mellitus, including the imperative need for glucose-level monitoring to optimize glycemic control. Leveraging chronoamperometric results as a foundational dataset and the in vivo hypoglycemic activity of nanoemulsion formulations, this research underscores the efficacy and accuracy of glucose concentration estimation, decision-making mechanism responses, and transdermal hypoglycemic treatment effects, within the proposed system.

Indexed as

closed loopdiabetes mellitusglucose monitoringhypoglycemic treatmentnoninvasivesoftware application

Identifiers

PMID39064398
PMCPMC11278575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.